Serena Hung

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

Peter A. Calabresi, Bernd C Kieseier, Douglas L. Arnold et al. · The Lancet Neurology · 2014 · 395 citations

Life Sciences, Immunology, Neurology +9

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Laura Fanning, Serena Hung, Aaron Ellenbogen et al. · Movement Disorders · 2019 · 194 citations · Full text

Life Sciences, Neurology, Pharmacology +17

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

Bernd C. Kieseier, Douglas L. Arnold, Laura J. Balcer et al. · Multiple Sclerosis Journal · 2014 · 113 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +12

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Douglas L. Arnold, Peter A. Calabresi, Bernd C. Kieseier et al. · BMC Neurology · 2014 · 45 citations · Full text

Life Sciences, Neurology, Clinical Neuroscience +13

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

Joleen T. White, Scott D. Newsome, Bernd C. Kieseier et al. · Therapeutic Advances in Neurological Disorders · 2016 · 29 citations · Full text

Life Sciences, Immunology, Pharmacology +15